{"id":33487,"date":"2025-05-20T14:00:00","date_gmt":"2025-05-20T12:00:00","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=33487"},"modified":"2025-09-10T08:37:22","modified_gmt":"2025-09-10T06:37:22","slug":"early-results-hero","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/en\/early-results-hero\/","title":{"rendered":"Promising early results from the HERO Trial for MECP2 Duplication Syndrome"},"content":{"rendered":"

Earlier this year, Alvin Luk attended the CRISPR Medicine Conference<\/em> in Copenhagen to provide an update on the HERO clinical trial for MECP2 Duplication Syndrome. Alvin\u2019s presentation is available for the community to watch on YouTube.<\/p>\n\n\n\n

In this video, you\u2019ll learn about Huidagene\u2019s experimental CRISPR-Cas13 therapy, HG204<\/strong>, and see the progress in the first treated child, three months after receiving the investigational drug. Skip to minute 26:00<\/strong> for video footage of the patient.<\/p>\n\n\n\n

These early results are very encouraging and further suggest that restoring MeCP2 protein levels could be a promising strategy to tackle MDS.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n<\/figure>\n\n\n\n

A second child has already been treated with HG204, and up to six patients are expected to be enrolled sequentially in this trial in China.<\/p>\n\n\n\n

\n
Watch the video:<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du […]<\/p>","protected":false},"author":1,"featured_media":33493,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,201],"tags":[],"class_list":["post-33487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite","category-recherche-fr"],"yoast_head":"\nR\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2<\/title>\n<meta name=\"description\" content=\"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/en\/early-results-hero\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/en\/early-results-hero\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-20T12:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T06:37:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome\",\"datePublished\":\"2025-05-20T12:00:00+00:00\",\"dateModified\":\"2025-09-10T06:37:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\"},\"wordCount\":167,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"articleSection\":[\"Actualit\u00e9\",\"Recherche\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\",\"url\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\",\"name\":\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"datePublished\":\"2025-05-20T12:00:00+00:00\",\"dateModified\":\"2025-09-10T06:37:22+00:00\",\"description\":\"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recherche\",\"item\":\"https:\/\/dupmecp2.eu\/category\/recherche-fr\/?lang=fr\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/en\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Promising early results from the HERO Trial for MECP2 Duplication Syndrome - DupMECP2","description":"Earlier this year, Alvin Luk attended the CRISPR Medicine Conference in Copenhagen to provide an update on the HERO clinical trial for MECP2 Duplication Syndrome. Alvin\u2019s presentation is available for the community to watch on YouTube.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/en\/early-results-hero\/","og_locale":"en_GB","og_type":"article","og_title":"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2","og_description":"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.","og_url":"https:\/\/dupmecp2.eu\/en\/early-results-hero\/","og_site_name":"DupMECP2","article_published_time":"2025-05-20T12:00:00+00:00","article_modified_time":"2025-09-10T06:37:22+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Caroline","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome","datePublished":"2025-05-20T12:00:00+00:00","dateModified":"2025-09-10T06:37:22+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/"},"wordCount":167,"commentCount":0,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","articleSection":["Actualit\u00e9","Recherche"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/","url":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/","name":"Promising early results from the HERO Trial for MECP2 Duplication Syndrome - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","datePublished":"2025-05-20T12:00:00+00:00","dateModified":"2025-09-10T06:37:22+00:00","description":"Earlier this year, Alvin Luk attended the CRISPR Medicine Conference in Copenhagen to provide an update on the HERO clinical trial for MECP2 Duplication Syndrome. Alvin\u2019s presentation is available for the community to watch on YouTube.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Recherche","item":"https:\/\/dupmecp2.eu\/category\/recherche-fr\/?lang=fr"},{"@type":"ListItem","position":3,"name":"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"EU","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/en\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts\/33487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/comments?post=33487"}],"version-history":[{"count":2,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts\/33487\/revisions"}],"predecessor-version":[{"id":33494,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts\/33487\/revisions\/33494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/media\/33493"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/media?parent=33487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/categories?post=33487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/tags?post=33487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}